KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Receivables: 2010-2022

Historic Receivables for TherapeuticsMD (TXMD) over the last 11 years, with Sep 2022 value amounting to $32.2 million.

  • TherapeuticsMD's Receivables fell 14.02% to $32.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $149.6 million, marking a year-over-year increase of 9.17%. This contributed to the annual value of $36.2 million for FY2021, which is 11.72% up from last year.
  • Per TherapeuticsMD's latest filing, its Receivables stood at $32.2 million for Q3 2022, which was down 29.79% from $45.8 million recorded in Q2 2022.
  • Over the past 5 years, TherapeuticsMD's Receivables peaked at $45.8 million during Q2 2022, and registered a low of $5.1 million during Q1 2018.
  • For the 3-year period, TherapeuticsMD's Receivables averaged around $31.8 million, with its median value being $33.5 million (2021).
  • Its Receivables has fluctuated over the past 5 years, first soared by 226.75% in 2019, then fell by 14.02% in 2022.
  • Quarterly analysis of 5 years shows TherapeuticsMD's Receivables stood at $11.1 million in 2018, then surged by 120.50% to $24.4 million in 2019, then soared by 32.74% to $32.4 million in 2020, then rose by 11.72% to $36.2 million in 2021, then declined by 14.02% to $32.2 million in 2022.
  • Its last three reported values are $32.2 million in Q3 2022, $45.8 million for Q2 2022, and $35.4 million during Q1 2022.